CL2012002541A1 - Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros. - Google Patents

Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.

Info

Publication number
CL2012002541A1
CL2012002541A1 CL2012002541A CL2012002541A CL2012002541A1 CL 2012002541 A1 CL2012002541 A1 CL 2012002541A1 CL 2012002541 A CL2012002541 A CL 2012002541A CL 2012002541 A CL2012002541 A CL 2012002541A CL 2012002541 A1 CL2012002541 A1 CL 2012002541A1
Authority
CL
Chile
Prior art keywords
compound
schizophrenia
anxiety
stress
pharmaceutical composition
Prior art date
Application number
CL2012002541A
Other languages
English (en)
Inventor
Hanbin Shan
Zhedong Yuan
Xueyan Zhu
Peng Zhang
Hongjuan Pan
Xiong Yu
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44599557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002541(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2012002541A1 publication Critical patent/CL2012002541A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuesto cristalino hidrato del hidrobromuro de agomelatina; método de preparación del compuesto; composición farmacéutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresión mayor, esquizofrenia, entre otros.
CL2012002541A 2010-03-17 2012-09-13 Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros. CL2012002541A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2010101262639A CN102190595A (zh) 2010-03-17 2010-03-17 阿戈美拉汀溴化氢水合物及其制备方法

Publications (1)

Publication Number Publication Date
CL2012002541A1 true CL2012002541A1 (es) 2013-01-11

Family

ID=44599557

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002541A CL2012002541A1 (es) 2010-03-17 2012-09-13 Compuesto cristalino hidrato del hidrobromuro de agomelatina; metodo de preparacion del compuesto; composicion farmaceutica; uso del compuesto para tratar trastornos del sueño, estres, ansiedad, depresion mayor, esquizofrenia, entre otros.

Country Status (39)

Country Link
US (1) US8729132B2 (es)
EP (1) EP2547650B1 (es)
JP (1) JP5634533B2 (es)
KR (1) KR101406736B1 (es)
CN (2) CN102190595A (es)
AP (1) AP3199A (es)
AU (1) AU2011229619B2 (es)
BR (1) BR112012023173B1 (es)
CA (1) CA2792430C (es)
CL (1) CL2012002541A1 (es)
CR (1) CR20120461A (es)
CU (1) CU20120136A7 (es)
CY (1) CY1117134T1 (es)
DK (1) DK2547650T3 (es)
EA (1) EA022066B1 (es)
EC (1) ECSP12012156A (es)
ES (1) ES2572427T3 (es)
GE (1) GEP20156232B (es)
GT (1) GT201200260A (es)
HK (1) HK1177732A1 (es)
HN (1) HN2012001923A (es)
HR (1) HRP20151343T1 (es)
HU (1) HUE026673T2 (es)
IL (1) IL221783A (es)
MA (1) MA34054B1 (es)
ME (1) ME02309B (es)
MX (1) MX2012010594A (es)
MY (1) MY160337A (es)
NI (1) NI201200141A (es)
NZ (1) NZ602451A (es)
PE (1) PE20130014A1 (es)
PL (1) PL2547650T3 (es)
PT (1) PT2547650E (es)
RS (1) RS54449B1 (es)
SG (1) SG183869A1 (es)
SI (1) SI2547650T1 (es)
TN (1) TN2012000436A1 (es)
UA (1) UA105424C2 (es)
WO (1) WO2011113363A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
WO2013170738A1 (zh) * 2012-05-14 2013-11-21 上海右手医药科技开发有限公司 阿戈美拉汀酸根复合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用

Also Published As

Publication number Publication date
BR112012023173B1 (pt) 2021-08-24
CU20120136A7 (es) 2012-12-17
TN2012000436A1 (en) 2014-01-30
ES2572427T3 (es) 2016-05-31
KR20120128713A (ko) 2012-11-27
PE20130014A1 (es) 2013-01-26
HUE026673T2 (en) 2016-07-28
NZ602451A (en) 2014-10-31
CN102892749A (zh) 2013-01-23
AU2011229619B2 (en) 2014-05-22
CN102892749B (zh) 2014-11-05
ECSP12012156A (es) 2012-12-28
CY1117134T1 (el) 2017-04-05
CA2792430C (en) 2015-12-08
SI2547650T1 (sl) 2016-02-29
KR101406736B1 (ko) 2014-06-12
UA105424C2 (uk) 2014-05-12
US8729132B2 (en) 2014-05-20
AP2012006493A0 (en) 2012-10-31
CA2792430A1 (en) 2011-09-22
US20130012592A1 (en) 2013-01-10
ME02309B (me) 2016-06-20
IL221783A (en) 2017-11-30
EP2547650B1 (en) 2015-11-04
HK1177732A1 (en) 2013-08-30
NI201200141A (es) 2012-11-09
WO2011113363A1 (en) 2011-09-22
HRP20151343T1 (hr) 2016-01-01
AP3199A (en) 2015-03-31
EA022066B1 (ru) 2015-10-30
DK2547650T3 (en) 2016-02-15
GT201200260A (es) 2013-11-18
HN2012001923A (es) 2015-09-14
PT2547650E (pt) 2015-11-30
AU2011229619A1 (en) 2012-09-27
PL2547650T3 (pl) 2016-06-30
GEP20156232B (en) 2015-01-26
JP2013522242A (ja) 2013-06-13
EP2547650A4 (en) 2013-09-18
EA201201293A1 (ru) 2013-04-30
MX2012010594A (es) 2012-10-03
EP2547650A1 (en) 2013-01-23
RS54449B1 (en) 2016-06-30
MY160337A (en) 2017-02-28
CR20120461A (es) 2012-11-29
BR112012023173A2 (pt) 2016-05-17
SG183869A1 (en) 2012-10-30
JP5634533B2 (ja) 2014-12-03
MA34054B1 (fr) 2013-03-05
CN102190595A (zh) 2011-09-21

Similar Documents

Publication Publication Date Title
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
IN2014DN09434A (es)
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BR112014020826A2 (pt) moduladores e métodos de uso
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
CL2013002664A1 (es) Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros.
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
CR20200220A (es) FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
CL2011002231A1 (es) Forma cristalina vi de la agomelatina; proceso de preparacion; composicion farmaceutica; y su uso para tratar estres, ansiedad, trastornos del sueño, enfermedades cardiovasculares, esquizofrenia, fobia, depresion, enfermedades del sistema digestivo.
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
GT201100300A (es) Piperidinas sustituidas